

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

75-796

ADMINISTRATIVE DOCUMENTS

ANDA 75-796 APPROVAL SUMMARY

PRODUCT: Levonorgestrel and Ethinyl Estradiol Tablets, USP

FIRM: Duramed Pharmaceuticals, Inc.

DOSAGE FORM: Tablet

STRENGTH: 0.10 mg/0.02 mg

cGMP STATEMENT/EIR UPDATE STATUS: Satisfactory
Acceptable EER on 05-MAR-2001

BIO STUDY: Approve, Per Bio Review Dated 04/19/00

VALIDATION: N/A, DS and DP are listed in the USP 24/NF 19

STABILITY: Three months accelerated (40°C/75%RH) and 9 months CRT (27°C±2°C) stability data for the unit dose blister container/closure system for Levonorgestrel and Ethinyl Estradiol Tablets lot C-0082 and Placebo Tablets lot C-0059, in 28 count (not over wrapped) and 10 count (overwrapped) were provided. The container/ closure system used for the stability study is equivalent to the system proposed for commercial use. All reported data are with in specifications as listed. Firm's stability data justifies a 24 month expiration date for the product.

Tests and specifications for the drug product on stability include: Appearance/description, container/closure, assay (of label claim), dissolution (levonorgestrel NLT in 60 minutes, ethinyl estradiol NLT in 60 minutes) and impurities/degradants (Total estradiol NMT

Individual Unknown . Tests and specifications for Placebo tablets on stability include , and

LABELING: Satisfactory, labeling review dated 03/22/01

STERILIZATION VALIDATION: N/A

SIZE OF BIO BATCH: Levonorgestrel and Ethinyl Estradiol
Batch # C-0082, tablets; Placebo Batch #S-0059,
 tablets.

SIZE OF STABILITY BATCHES: Stability batches are the same as
the test/bio-batches.

PROPOSED PRODUCTION BATCHES: The proposed maximum production
batch size for the Levonorgestrel and Ethinyl Estradiol
tablets is lets and for the Placebo tablets is
-, ablets. The manufacturing process for production
batches remains the same as that for the ANDA batches.

CHEMIST: *U.S. ATWAL, Ph.D.*

DATE:

SUPERVISOR: *D. Gill, Ph.D.*

DATE:

AUG 12 2000

38. CHEMISTRY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 75-796 APPLICANT: Duramed Pharmaceuticals, Inc.

DRUG PRODUCT: Levonorgestrel and Ethinyl Estradiol
Tablets, USP 0.100 mg/0.02 mg

The deficiencies presented below represent MAJOR deficiencies.

A. Deficiencies:

1. ---

2. F

3. ---

4. F
M
f
l

5. You indicated that the amount of material
sults
e.
ment

6. Manufacturing record

specification

Page(s) 1

Contain Trade Secret,

Commercial/Confidential

Information and are not

releasable.

8/12/00


15. Please explain why you placed intermediates in stability. prep

16. Please revise your specifications for dissolution according to current USP specifications and provide revised stability protocol and finished product specification sheet.

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comments in your response:

1. A satisfactory CGMP compliance evaluation for the firms referenced in the ANDA is required for approval. We have requested an evaluation from the Division of Manufacturing and Product Quality.
2. Labeling portion of your application is under review. Deficiencies, if any, will be conveyed to you under separate cover.
3. Even though you have provided room temperature stability data for the intermediates in support of 12 months expiration dating, the expiration dating period for the tablets manufactured from the corresponding intermediates still will be counted from the date of manufacture of the powder intermediates.

Sincerely yours,


Rashmikant M. Patel, Ph.D.
Director
Division of Chemistry I
Office of Generic Drugs
Center for Drug Evaluation and Research